Ghrelin News and Research

RSS

Ghrelin is a hormone produced mainly by P/D1 cells lining the fundus of the human stomach and epsilon cells of the pancreas that stimulates appetite. Ghrelin levels increase before meals and decrease after meals. It is considered the counterpart of the hormone leptin, produced by adipose tissue, which induces satiation when present at higher levels. Ghrelin is also produced in the hypothalamic arcuate nucleus where it stimulates the secretion of growth hormone from the anterior pituitary gland.

Study offers clearer understanding of how obese people can sustain weight loss

Maintaining a stable weight loss is the biggest struggle for obese individuals, yet new research from University of Copenhagen have allowed researchers new insights into the complex processes involved in obesity and especially weight loss in obesity. It is now possible to offer overweight people a clearer understanding of how to sustain weight loss.

16 Apr 2016

Bariatric arterial embolization safe, effective in sustaining weight loss in severely obese people

Findings from the early phase of a clinical trial led by Johns Hopkins investigators indicates that a new, minimally invasive weight loss treatment known as bariatric arterial embolization is safe and effective in sustaining weight loss in severely obese people.

4 Apr 2016

Bariatric arterial embolization could offer viable, safe alternative to surgical weight-loss treatments

A safe, new, minimally invasive treatment, developed by interventional radiologists, led to sustained weight loss in severely obese people, according to research presented at the Society of Interventional Radiology's 2016 Annual Scientific Meeting. Researchers said the treatment--bariatric arterial embolization (BAE)--could offer individuals a viable, safe alternative to surgical weight-loss treatments.

4 Apr 2016

Exercise more effective than food restriction in helping reduce daily calorie consumption

Scientists at Loughborough University have found exercising is more effective than food restriction in helping limit daily calorie consumption.

9 Mar 2016

Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announce that they have entered into distribution, license and supply agreements with Mundipharma and its network of independent associated companies granting exclusive rights to anamorelin in Norway, Finland, Sweden, Denmark and Iceland.

16 Feb 2016

Irregular sleep schedules linked to adverse metabolic health in midlife women

A new study suggests that frequent shifts in sleep timing may be related to adverse metabolic health among non-shift working, midlife women.

1 Feb 2016

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.

30 Nov 2015

Interaction between two brain proteins has substantial effect on memory formation

In a new study that could have implications for future drug discovery efforts for a number of neurodegenerative diseases, scientists from the Florida campus of The Scripps Research Institute (TSRI) have found that the interaction between a pair of brain proteins has a substantial and previously unrecognized effect on memory formation.

20 Nov 2015

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).

24 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

Rhythm Metabolic completes $40 million Series A financing

Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.

13 Aug 2015

Aeterna Zentaris selects Ergomed to manage Phase 3 clinical study of Macrilen

Aeterna Zentaris Inc. announced today that it has executed a definitive agreement with Ergomed PLC, pursuant to which Ergomed will manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD").

25 Jun 2015

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

Rhythm announced today the initiation of two Phase 2 clinical trials focused on evaluating the safety and effectiveness of setmelanotide (RM-493), the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of Prader-Willi Syndrome (PWS) and POMC-null obesity.

4 Jun 2015

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

Detailed data will be presented from the two Phase I trials conducted in 76 healthy volunteers and overweight or obese subjects...

26 May 2015

Aeterna Zentaris plans to conduct Macrilen Phase 3 clinical study for AGHD

Aeterna Zentaris Inc. today announced plans to conduct a new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD"), as well as a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarization.

13 Apr 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao.

26 Mar 2015

Physicians develop new quality measures for treatment of childhood obstructive sleep apnea

A work group of physicians from leading academic medical centers across the country, including NYU Langone Medical Center, has developed new quality measures for the detection and treatment of childhood obstructive sleep apnea (OSA), a potentially morbid, life-altering condition that affects hundreds of thousands of children and adolescents nationwide.

16 Mar 2015

Obese females with eating/behavioral characteristic have impaired metabolism

In obese females, a close relationship may exist between their disinhibition (detrimental eating and behavioral characteristics) that limits successful weight loss, and impaired metabolism, new research shows.

9 Mar 2015

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.

3 Mar 2015